Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2009
Reporting Period: Second Quarter ended June 30, 2009
This filing serves as a notification that the company announced its financial results for the quarter ended June 30, 2009. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the announcement of the quarterly results.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release for the full announcement but does not include specific management commentary, guidance, or outlook within the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: None reported in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 6, 2009) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical development milestones mentioned in the full press release, as this filing only announces the results.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the exhibit.
- Check for any updated guidance on product timelines or regulatory approvals in the full announcement.